- Palabras clave > advertisement and promotion
- Palabras clave > Code of Conduct for Pharmaceutical Advertising
- Palabras clave > drug promotion
- Palabras clave > Ethical Criteria for Medicinal Drug Promotion
- Palabras clave > ethical practices and standards
- Palabras clave > marketing practices
- Palabras clave > pharmaceutical promotions - regulation
- Palabras clave > pharmaceutical regulation
- Palabras clave > regulation - pharmaceutical markets
- Palabras clave > regulatory framework
(2015; 99 pages)
While international regulatory standards for pharmaceutical promotion exist, many countries, especially developing countries, are not able to adequately regulate pharmaceutical promotion due to lack of resources needed for pharmaceutical regulation or do not simply prioritize regulation of pharmaceutical promotion. In many instances, only self-regulation is implemented by the industrial associations, and the pharmaceutical and advertising industries. This set-up however may be problematic due to inherent conflict of interest in self-regulation.
The regulation of medicines promotion was identified as a critical priority in the Philippines in order to encourage rational use, ensure reasonable pricing of medicines and promote growth of SMEs. A system for pharmaceutical promotion which involves the civil society and other non-state actors as partners in the oversight and monitoring of promotional activities will be significant especially considering the limited resources allotted in the regulation of pharmaceutical promotions. Specific guidelines that define ethical promotion and identify penalties for infringements may also be helpful in ensuring quality use of medicines by patients and at the same time helping the pharmaceutical industry sustain their operations.
The general objective of this study is to propose various regulatory models on pharmaceutical promotions in the Philippines that articulate clear and active involvement of civil society and other non-government stakeholders.
Specifically it aims to:
- present examples/cases of effective civil society-participated regulatory models for pharmaceutical promotions in other countries;
- describe the current regulation process for pharmaceutical promotions in the country for the purpose of identifying its strengths, weaknesses and areas for improvement;
- propose alternative regulatory models for pharmaceutical promotions involving civil society and other non-government stakeholders; and,
- identify needs, resources and other requirements to support implementation of proposed alternative regulatory models.